Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANDRA MARCHESE JOHNSON

Allopathic & Osteopathic Physicians Dermatology

NPI
1447256102
CMS profile
19756
Location
FORT SMITH, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$43,260.61

181 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANDRA MARCHESE JOHNSON

NPI 1447256102 · CMS profile ID 19756

Allopathic & Osteopathic Physicians / Dermatology

FORT SMITH, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447256102?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANDRA MARCHESE JOHNSON, NPI 1447256102, CMS profile ID 19756. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447256102?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SANDRA MARCHESE JOHNSON, NPI 1447256102, CMS profile ID 19756. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447256102?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SANDRA MARCHESE JOHNSON, NPI 1447256102, CMS profile ID 19756, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447256102?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

181 matching records · $43,260.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 181 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 181.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SUN PHARMACEUTICAL INDUSTRIES INC. $21.5810/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851926677 CMS
Amgen Inc. $76.7010/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428511 CMS
LEO Pharma Inc. $13.3110/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842210425 CMS
Galderma Laboratories, L.P. $10.7810/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855282387 CMS
PFIZER INC. $13.5509/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833230197 CMS
AbbVie Inc. $17.5609/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794981879 CMS
Janssen Biotech, Inc. $12.6909/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788244275 CMS
Regeneron Healthcare Solutions, Inc. $19.7209/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809590435 CMS
Lilly USA, LLC $19.1509/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818698017 CMS
Amgen Inc. $21.7709/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428435 CMS
AbbVie Inc. $14.7209/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794981875 CMS
UCB, Inc. $9.9009/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807412575 CMS
AbbVie Inc. $0.5909/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794981871 CMS
Novartis Pharmaceuticals Corporation $13.0309/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812735001 CMS
Regeneron Healthcare Solutions, Inc. $1,175.6809/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809590433 CMS
Galderma Laboratories, L.P. $10.7809/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855282385 CMS
GENZYME CORPORATION $18.1309/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843507211 CMS
Amgen Inc. $179.0209/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428439 CMS
Amgen Inc. $166.6609/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428447 CMS
Amgen Inc. $10.2109/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428471 CMS
Amgen Inc. $10.0009/02/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428475 CMS
LEO Pharma Inc. $12.7309/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842210413 CMS
Amgen Inc. $132.7208/31/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428443 CMS
Amgen Inc. $3,000.0008/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428451 CMS
Amgen Inc. $500.0008/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428459 CMS
Amgen Inc. $3.6008/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428467 CMS
PFIZER INC. $13.5608/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832850183 CMS
Janssen Biotech, Inc. $16.6508/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788244261 CMS
Amgen Inc. $3,000.0008/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428455 CMS
Amgen Inc. $500.0008/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428463 CMS
Amgen Inc. $17.2508/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428483 CMS
AbbVie Inc. $12.3508/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794981867 CMS
Amgen Inc. $124.3408/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428479 CMS
Lilly USA, LLC $18.0608/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818696523 CMS
Janssen Biotech, Inc. $10.9308/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788244283 CMS
GENZYME CORPORATION $20.1608/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843507163 CMS
Amgen Inc. $18.7208/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428431 CMS
Regeneron Healthcare Solutions, Inc. $8.0908/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809590429 CMS
Regeneron Healthcare Solutions, Inc. $194.8808/10/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809590431 CMS
UCB, Inc. $12.6008/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807386377 CMS
LEO Pharma Inc. $11.7108/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842210407 CMS
Galderma Laboratories, L.P. $12.4908/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855282383 CMS
Novartis Pharmaceuticals Corporation $16.3408/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812735023 CMS
AbbVie Inc. $14.2807/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794981863 CMS
Lilly USA, LLC $1.4407/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818747313 CMS
Lilly USA, LLC $11.2907/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818747315 CMS
Amgen Inc. $24.4507/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826428427 CMS
GENZYME CORPORATION $99.2807/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843507175 CMS
GENZYME CORPORATION $5,280.0007/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843507177 CMS
GENZYME CORPORATION $920.8907/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843507181 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $67,839.82 171
PY2020 $8,443.88 121
PY2021 $43,260.61 181
PY2022 $72,601.92 205
PY2023 $89,213.45 233
PY2024 $140,582.72 252
PY2025 $120,961.93 186

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $192,958.83 1
PY2025 Principal investigator $833,685.14 201
PY2024 Recipient $285,510.49 2
PY2024 Principal investigator $1,148,397.35 729
PY2023 Recipient $462.58 2
PY2023 Principal investigator $707,269.73 806
PY2022 Recipient $372.00 2
PY2022 Principal investigator $297,892.64 48
PY2021 Recipient $2,837.75 2
PY2021 Principal investigator $786,138.05 47
PY2020 Recipient $201.74 2
PY2020 Principal investigator $619,598.88 82
PY2019 Recipient $34,251.57 5
PY2019 Principal investigator $1,052,270.17 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

202 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202532452
Recipient Nielsen BioSciences, Inc. $192,958.83 12/30/2025 Covered Recipient Physician CFW-3A No dispute reported 06/30/2026 1215535693
Principal investigator 1 SANOFI US SERVICES INC. $14,735.00 12/22/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081429
Principal investigator 1 Janssen Research & Development, LLC $3,202.00 12/19/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425332
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,174.20 12/19/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223290002
Principal investigator 1 Incyte Corporation $1,142.90 12/08/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544514
Principal investigator 1 ABBVIE INC. $1,594.10 12/04/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527258
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544497
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544502
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544509
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544526
Principal investigator 1 Incyte Corporation $49.77 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544537
Principal investigator 1 Incyte Corporation $1,500.00 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544550
Principal investigator 1 Incyte Corporation $700.00 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544562
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544568
Principal investigator 1 Incyte Corporation $9.48 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544574
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,286.20 12/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289075
Principal investigator 1 Incyte Corporation $1,235.70 11/10/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544520
Principal investigator 1 Novartis Pharmaceuticals Corporation $157,436.44 11/10/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190305483
Principal investigator 1 Incyte Corporation $54.76 11/05/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544556
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,243.18 11/05/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223288063
Principal investigator 1 ABBVIE INC. $1,568.10 11/04/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520289
Principal investigator 1 SANOFI US SERVICES INC. $6,844.00 11/04/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081425
Principal investigator 1 Janssen Research & Development, LLC $1,262.00 11/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425404
Principal investigator 1 Janssen Research & Development, LLC $1,683.00 10/31/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area No dispute reported 06/30/2026 1175425340
Principal investigator 1 Incyte Corporation $12,218.20 10/22/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544544
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,002.80 10/22/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287299
Principal investigator 1 Eli Lilly and Company $14,241.00 10/14/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187881650
Principal investigator 1 ABBVIE INC. $4,560.00 10/09/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202514191
Principal investigator 1 Incyte Corporation $1,728.90 10/08/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544532
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,387.82 10/08/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223286493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,082.10 10/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223286089
Principal investigator 1 Janssen Research & Development, LLC $1,262.00 09/29/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425380
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,655.49 09/23/2025 Non-covered Recipient Entity
Johnson Dermatology Pllc
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190305021
Principal investigator 1 SANOFI US SERVICES INC. $15,052.00 09/15/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081421
Principal investigator 1 Incyte Corporation $188.00 09/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544405
Principal investigator 1 Incyte Corporation $55.00 09/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544419
Principal investigator 1 Incyte Corporation $231.00 09/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544424
Principal investigator 1 Incyte Corporation $840.00 09/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544429
Principal investigator 1 Incyte Corporation $4,548.00 09/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544439
Principal investigator 1 Incyte Corporation $1,598.00 09/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544444
Principal investigator 1 Incyte Corporation $96.00 09/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544460
Principal investigator 1 Incyte Corporation $810.00 09/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544467
Principal investigator 1 Incyte Corporation $781.50 09/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544473
Principal investigator 1 Incyte Corporation $1,105.60 09/10/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544360
Principal investigator 1 Incyte Corporation $1,373.00 09/10/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544365
Principal investigator 1 ABBVIE INC. $2,859.30 09/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202508218
Principal investigator 1 Incyte Corporation $20.00 09/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544353
Principal investigator 1 Incyte Corporation $1,000.00 09/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544372
Principal investigator 1 Incyte Corporation $86.00 09/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544382
Principal investigator 1 Incyte Corporation $50.00 09/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544388
Principal investigator 1 Incyte Corporation $232.00 09/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544480
Principal investigator 1 Incyte Corporation $94.50 09/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544493
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,919.50 09/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285079
Principal investigator 1 Janssen Research & Development, LLC $3,175.00 08/25/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425348
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,319.81 08/13/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284215
Principal investigator 1 ABBVIE INC. $1,835.90 08/05/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501406
Principal investigator 1 Incyte Corporation $1,728.90 08/04/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544348
Principal investigator 1 Janssen Research & Development, LLC $1,427.00 08/04/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175425394
Principal investigator 1 Janssen Research & Development, LLC $1,913.00 08/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425375
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,798.80 08/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283755
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,190.50 08/01/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283757
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,082.03 07/24/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190305481
Principal investigator 1 SANOFI US SERVICES INC. $4,587.65 07/21/2025 Non-covered Recipient Entity
Johnson Dermatology
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226081417
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,628.36 07/18/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282838
Principal investigator 1 Incyte Corporation $192.00 07/16/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544377
Principal investigator 1 Incyte Corporation $126.00 07/16/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544393
Principal investigator 1 Incyte Corporation $950.00 07/16/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544398
Principal investigator 1 Incyte Corporation $774.00 07/16/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544412
Principal investigator 1 Incyte Corporation $220.00 07/16/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544435
Principal investigator 1 Incyte Corporation $232.00 07/16/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240544486
Principal investigator 1 SANOFI US SERVICES INC. $13,204.00 07/14/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081413
Principal investigator 1 Incyte Corporation $1,104.80 07/09/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544451
Principal investigator 1 Incyte Corporation $1,381.00 07/09/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544454
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,005.42 07/09/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282428
Principal investigator 1 ABBVIE INC. $4,695.20 07/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495189
Principal investigator 1 Janssen Research & Development, LLC $4,387.00 06/27/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425400
Principal investigator 1 SANOFI US SERVICES INC. $4,307.00 06/16/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081405
Principal investigator 1 ABBVIE INC. $9,738.50 06/10/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202490787
Principal investigator 1 Incyte Corporation $1,104.80 06/06/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544011
Principal investigator 1 Incyte Corporation $1,381.00 06/06/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544315
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,119.70 06/06/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280930
Principal investigator 1 ABBVIE INC. $3,098.50 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202489735
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543999
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544142
Principal investigator 1 Incyte Corporation $20.60 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544155
Principal investigator 1 Incyte Corporation $54.76 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544181
Principal investigator 1 Incyte Corporation $68.70 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544186
Principal investigator 1 Incyte Corporation $9.54 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544191
Principal investigator 1 Incyte Corporation $32.36 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544202
Principal investigator 1 Incyte Corporation $49.36 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544208
Principal investigator 1 Incyte Corporation $48.54 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544213
Principal investigator 1 Incyte Corporation $9.72 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544220
Principal investigator 1 Incyte Corporation $80.15 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544227
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544304
Principal investigator 1 Incyte Corporation $32.88 06/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,000.00 05/28/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280438
Principal investigator 1 Amgen Inc. $29.31 05/27/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC PLLC
A Phase 3b, Multi Center, Open-label, Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1246643225
Principal investigator 1 Eli Lilly and Company $2,645.84 05/20/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187885536
Principal investigator 1 SANOFI US SERVICES INC. $7,727.00 05/19/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081409
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,461.31 05/16/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279928
Principal investigator 1 Janssen Research & Development, LLC $1,995.00 05/09/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175425354
Principal investigator 1 ABBVIE INC. $1,683.80 05/07/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202482811
Principal investigator 1 Incyte Corporation $1,242.90 05/07/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544263
Principal investigator 1 Incyte Corporation $135.40 05/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544108
Principal investigator 1 Incyte Corporation $48.60 05/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544291
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,008.72 05/01/2025 Non-covered Recipient Entity
Johnson Dermatology, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432990
Principal investigator 1 Janssen Research & Development, LLC $2,474.00 04/28/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425417
Principal investigator 1 SANOFI US SERVICES INC. $14,514.00 04/14/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081401
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,555.00 04/11/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223277960
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,842.70 04/11/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278028
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,397.33 04/10/2025 Non-covered Recipient Entity
Johnson Dermatology
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235996427
Principal investigator 1 Incyte Corporation $1,242.90 04/07/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543995
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,764.68 04/04/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277594
Principal investigator 1 ABBVIE INC. $4,827.80 04/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202469097
Principal investigator 1 Incyte Corporation $127.20 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544005
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544020
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544027
Principal investigator 1 Incyte Corporation $0.31 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544033
Principal investigator 1 Incyte Corporation $53.00 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544038
Principal investigator 1 Incyte Corporation $7.29 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544043
Principal investigator 1 Incyte Corporation $16.18 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544050
Principal investigator 1 Incyte Corporation $24.68 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544055
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544059
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544064
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544069
Principal investigator 1 Incyte Corporation $34.35 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544077
Principal investigator 1 Incyte Corporation $49.36 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544082
Principal investigator 1 Incyte Corporation $0.62 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544089
Principal investigator 1 Incyte Corporation $68.70 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544096
Principal investigator 1 Incyte Corporation $32.36 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544101
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544114
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544119
Principal investigator 1 Incyte Corporation $5.38 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544123
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544132
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544137
Principal investigator 1 Incyte Corporation $127.20 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544149
Principal investigator 1 Incyte Corporation $84.80 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544159
Principal investigator 1 Incyte Corporation $84.80 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544165
Principal investigator 1 Incyte Corporation $10.60 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544171
Principal investigator 1 Incyte Corporation $21.20 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544177
Principal investigator 1 Incyte Corporation $14.58 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544234
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544236
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544243
Principal investigator 1 Incyte Corporation $16.44 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544251
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544257
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544268
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544273
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544278
Principal investigator 1 Incyte Corporation $10.76 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544285
Principal investigator 1 Incyte Corporation $42.40 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544298
Principal investigator 1 Incyte Corporation $63.60 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544323
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544330
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544335
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240544342
Principal investigator 1 SANOFI US SERVICES INC. $4,668.00 04/02/2025 Non-covered Recipient Entity
Johnson Dermatology
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226081396
Principal investigator 1 Janssen Research & Development, LLC $3,933.00 03/24/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425370
Principal investigator 1 SANOFI US SERVICES INC. $4,284.00 03/24/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081388
Principal investigator 1 Incyte Corporation $1,381.00 03/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543876
Principal investigator 1 Incyte Corporation $1,225.40 03/12/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543890
Principal investigator 1 ABBVIE INC. $6,880.80 03/07/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202460383
Principal investigator 1 Incyte Corporation $11.45 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543907
Principal investigator 1 Incyte Corporation $5.30 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543913
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543918
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543925
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543931
Principal investigator 1 Incyte Corporation $124.54 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543971
Principal investigator 1 Incyte Corporation $270.80 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543977
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543983
Principal investigator 1 Incyte Corporation $16.44 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543989
Principal investigator 1 Janssen Research & Development, LLC $1,459.00 03/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425386
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,268.90 02/26/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275633
Principal investigator 1 SANOFI US SERVICES INC. $12,300.00 02/24/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081385
Principal investigator 1 SANOFI US SERVICES INC. $3,715.00 02/24/2025 Non-covered Recipient Entity
Johnson Dermatology
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226081392
Principal investigator 1 Incyte Corporation $1,466.00 02/19/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543841
Principal investigator 1 Incyte Corporation $1,582.30 02/19/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543897
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,663.17 02/14/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275323
Principal investigator 1 Janssen Research & Development, LLC $5,626.00 02/10/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175425360
Principal investigator 1 Janssen Research & Development, LLC $4,960.00 02/07/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175425412
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,064.38 02/07/2025 Non-covered Recipient Entity
Johnson Dermatology, PLLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432986
Principal investigator 1 ABBVIE INC. $9,834.40 02/06/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202447283
Principal investigator 1 Incyte Corporation $0.98 02/06/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240543883
Principal investigator 1 Incyte Corporation $1.96 02/06/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240543901
Principal investigator 1 SANOFI US SERVICES INC. $8,449.20 02/04/2025 Non-covered Recipient Entity
Johnson Dermatology
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226081375
Principal investigator 1 SANOFI US SERVICES INC. $3,245.00 02/04/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081380
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,591.49 02/03/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274659
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 01/31/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surf No dispute reported 06/30/2026 1175425364
Principal investigator 1 Eli Lilly and Company $2,930.28 01/27/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187883170
Principal investigator 1 Incyte Corporation $1,061.40 01/27/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543853
Principal investigator 1 Incyte Corporation $2,130.00 01/27/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543858
Principal investigator 1 Eli Lilly and Company $65,410.00 01/21/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY PLLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187885538
Principal investigator 1 SANOFI US SERVICES INC. $8,356.00 01/21/2025 Non-covered Recipient Entity
Johnson Dermatology
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226081433
Principal investigator 1 Incyte Corporation $1,504.00 01/17/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543836
Principal investigator 1 Incyte Corporation $1,213.10 01/17/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543937
Principal investigator 1 Incyte Corporation $1,784.70 01/10/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1240543846
Principal investigator 1 Amgen Inc. $51,075.19 01/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY CLINIC PLLC
A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis No dispute reported 06/30/2026 1246643217
Principal investigator 1 Incyte Corporation $270.80 01/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543864
Principal investigator 1 Incyte Corporation $4.86 01/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543870
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543947
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543953
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543959
Principal investigator 1 Incyte Corporation $16.44 01/02/2025 Non-covered Recipient Entity
JOHNSON DERMATOLOGY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240543965